Making Medicine Incubate Coalition

Joe Allen, Executive Director of The Bayh-Dole Coalition, was at the forefront of the Bayh-Dole Act back in December 1980, which allowed researchers to own inventions resulting from federally funded research. However, 43 years later, the March-In Rights framework proposed by the Biden administration threatens to weaken America’s innovation. In this episode, Joe delves into the potential implications of this framework on drug pricing, the pipeline, and overall innovation.

Join us as we discuss:
The significance of the Bayh-Dole Act and intellectual property in transforming how America drives innovation.Why public-private partnerships and collaboration in the medical field are key for funding research projects.The implications of enacting March-In Rights on the drug development pipeline

How can we create better outcomes for cancer patients?

That’s the big goal Mohit Manrao is aiming for in his work as SVP & Head of US Oncology at AstraZeneca. In this episode, Mohit shares his perspective on the future of oncology and the pursuit of patient-centric care in a post-Inflation Reduction Act world.

Join us as we discuss:
AstraZeneca's goal of launching 15 new drugs by 2030Solving for disparities in care and improving health equityTimeline for drug development and its effect on patient outcomes

Can we create a future healthcare system that is accessible and affordable for all patients?

That’s the major question that Mary R. Grealy, CEO of Healthcare Leadership Council, is trying to answer through her work. Mary, a former speech pathologist turned lawyer, shares insights from her unique journey from the healthcare field to advocating for patient-centered, value-based healthcare systems. In this wide-ranging conversation, Mary shares the challenges faced in the industry but also her hope for a future where patients are empowered through collaboration and innovation.

Join us as we discuss:
Why collaboration between stakeholders is keyPractical tips for advocates to make a compelling case to CongressThe potential effects of the new price-setting systemThe impact of proposed legislation on treatments and cures

With recent movement in healthcare including President Biden’s Cancer Moonshot and the Inflation Reduction Act, one thing is clear: American healthcare is at a crossroads.

As we begin to tackle the conversation of healthcare reform, how can we rebuild the system around patients?

In this episode, MacKay Jimeson, Executive Director of The Patient Access & Affordability Project at Patients Rising, joins the show to explain how the system was never designed for patients, the benefits of a patient-centric system, and what the future holds for the industry.

Join us as we discuss:
Why patient-centricity is notably absent in our healthcare systemMacKay’s op-ed in response to President Biden’s SOTUThe impact of The Inflation Reduction Act and Centers for Medicare & Medicaid Services on today’s healthcare landscapeThe true human impact of medicines

MacKay’s Op-Ed: https://www.statnews.com/2023/02/09/state-of-the-union-highlights-americas-awkward-conversation-on-science-medicine-and-financing-the-development-of-new-medicines/

MacKay’s Bio:
https://accessandaffordability.org/person/02-mackay-jimeson/

Even though 80% of the household decisions around health are made by women, only 4% of research and funding goes towards women’s health research.

In today’s episode, Natalie Buford-Young, Chief Executive Officer at Springboard Enterprises, joins us to discuss Springboard’s mission and how they are exploring a designated network to create pathways for emerging female innovators.

We also get to hear about Natalie's experience testifying on the Hill to advocate for reducing the decline of women's entrepreneurship.

Join us as we discuss:
· Innovation in digital health and life sciences;
· The Women's Health Innovation Coalition; and
· Increasing diversity in clinical trials.

Runaway inflation and economic instability is terrible for just about everybody, but are efforts to tackle this problem creating more?
To answer that, Kirsten Axelsen, Senior Policy Advisor at DLA Piper, joins the show to break down all the effects The Inflation Reduction act is having upon medicine,
We discuss:The potential negative impacts on small-molecule medicineHow the act affects patents and generic medicineWhy we may see declines in small-molecule medicine research